In a third-quarter earnings call this week, Thermo Fisher Scientific reported 6 percent revenue growth to $2.68 billion and hinted at upcoming releases of new mass spectrometry products.

Discussing R&D spending, CEO Marc Casper said that investors would "see new applications and new technologies and mass spec coming out." He later added, with regard to the company's mass spec business, that "we have leading technology, leading position, a great suite of new introductions… coming out."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.